COLUMBIA-1: Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Trial Identifier: D910CC00001
Sponsor: MedImmune, LLC
NCTID:: NCT04068610
Start Date: September 2019
Primary Completion Date: October 2022
Study Completion Date: October 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Spanish (US) Translation
French (Canadian) Translation
French Translation

Trial Locations

Country Location
AU Blacktown, AU, 2148
AU Clayton, AU, 3168
AU Heidelberg, AU, 3084
AU Melbourne, AU, 3000
AU Waratah, AU, 2298
CA, AB Calgary, AB, CA, T2N 4N2
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, ON Oshawa, ON, CA, L1G 2B9
CA, ON Toronto, ON, CA, M5G 1X6
ES Barcelona, ES, 08035
ES Barcelona, ES, 08916
ES Madrid, ES, 28046
ES Madrid, ES, 28027
ES Majadahonda, ES, 28222
ES Valencia, ES, 46010
FR Bordeaux, FR, 33076
FR Lille, FR, 59000
FR Nantes, FR, 44000
FR Paris, FR, 75015
FR Paris, FR, 75012
FR Toulouse Cedex 9, FR, 31059
FR Villejuif, FR, 94805
US, CA Los Angeles, CA, US, 90095
US, CA Sacramento, CA, US, 95817
US, CT New Haven, CT, US, 06510
US, MI Ann Arbor, MI, US, 48109
US, NC Chapel Hill, NC, US, 27599
US, NV Las Vegas, NV, US, 89169
US, NY New York, NY, US, 10065
US, OH Canton, OH, US, 44718
US, PA Philadelphia, PA, US, 19104
US, RI Providence, RI, US, 02903
US, TN Chattanooga, TN, US, 37404
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030
US, VA Charlottesville, VA, US, 22908